Psoriasis: real-world data supports efficacy of secukinumab

  • Thaçi D & al.
  • J Eur Acad Dermatol Venereol
  • 21 Sep 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Secukinumab is associated with clinical benefit in patients with moderate to severe plaque psoriasis, according to results from the real-world PROSPECT study.

Why this matters

  • Cohort included prior and concurrent users of other systemic therapy.

Key results

  • At week 24, secukinumab was associated with 86.1% of patients achieving ≥75% improvement in the Psoriasis Area and Severity Index (PASI75).
    • 68.5% of patients achieved PASI90.
    • 39.7% of patients achieved PASI100.
  • In a subgroup analysis of patients naive to systemic therapies, 92.8% achieved PASI75, 84.3% achieved PASI90, and 66.3% achieved PASI100.
  • In patients previously treated with biologics, 78.1% achieved PASI75, 54.8% achieved PASI90, and 29.0% achieved PASI100.
  • 45.9% of patients experienced an adverse event.
    • Most common were nasopharyngitis (8.7%), pruritus (2.9%), and headache (2.4%).
    • 4.1% of patients experienced a serious adverse event.
    • 6.9% of patients discontinued because of an adverse event.

Study design

  • Efficacy data for 1323 of 1988 patients from an ongoing prospective study completing 24 weeks of treatment with secukinumab for moderate to severe plaque psoriasis.
  • Of the overall cohort, 90.9% had received prior systemic therapy and 44.3% were receiving concomitant treatment.
  • Funding: Novartis Pharma GmbH.

Limitations

  • No comparator group.
  • Short study length.